P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer

  • Van Veggel B
  • Van Der Wekken A
  • Hashemi S
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This artice is free to access.

Abstract

Methods: 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands. Data were obtained retrospectively. EGFR mutation status was assessed by next-generation sequencing. Progression free survival (PFS), disease control rate (DCR) and objective response rate (ORR) were assessed using RECIST v1.1.

Cite

CITATION STYLE

APA

Van Veggel, B., Van Der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., … De Langen, J. (2018). P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 13(10), S815. https://doi.org/10.1016/j.jtho.2018.08.1437

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free